BioNTech is winding down all COVID-19 vaccine production in Germany, handing it over to Pfizer.
Closing production sites in Idar-Oberstein, Marburg, Tübingen (Germany), and Singapore, with closures by end of 2027.
Up to 1,860 jobs at risk due to overcapacity and cost-cutting.
Retaining main base in Mainz and offices in Berlin and Munich.
Shifting focus to cancer and other illness research.